S

SSY Group Ltd
HKEX:2005

Watchlist Manager
SSY Group Ltd
HKEX:2005
Watchlist
Price: 3.73 HKD -2.1% Market Closed
Market Cap: 11B HKD
Have any thoughts about
SSY Group Ltd?
Write Note

SSY Group Ltd
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

SSY Group Ltd
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
S
SSY Group Ltd
HKEX:2005
Long-Term Investments
HK$420.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
115%
G
Grand Pharmaceutical Group Ltd
HKEX:512
Long-Term Investments
HK$8.4B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
54%
U
United Laboratories International Holdings Ltd
HKEX:3933
Long-Term Investments
ÂĄ7.6m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
-42%
Sino Biopharmaceutical Ltd
HKEX:1177
Long-Term Investments
ÂĄ27.7B
CAGR 3-Years
17%
CAGR 5-Years
78%
CAGR 10-Years
36%
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Long-Term Investments
HK$8.6B
CAGR 3-Years
1%
CAGR 5-Years
10%
CAGR 10-Years
N/A
H
HUTCHMED (China) Ltd
HKEX:13
Long-Term Investments
$80.5m
CAGR 3-Years
-12%
CAGR 5-Years
-11%
CAGR 10-Years
-3%
No Stocks Found

SSY Group Ltd
Glance View

Market Cap
11.1B HKD
Industry
Pharmaceuticals

SSY Group Ltd. is an investment holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company employs 4,800 full-time employees The company went IPO on 2005-12-20. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Intrinsic Value
5.41 HKD
Undervaluation 31%
Intrinsic Value
Price
S

See Also

What is SSY Group Ltd's Long-Term Investments?
Long-Term Investments
420.2m HKD

Based on the financial report for Jun 30, 2024, SSY Group Ltd's Long-Term Investments amounts to 420.2m HKD.

What is SSY Group Ltd's Long-Term Investments growth rate?
Long-Term Investments CAGR 10Y
115%

Over the last year, the Long-Term Investments growth was 5%.

Back to Top